Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD5QRS)

• Drug Name: Ranirestat Drug Info
• Synonyms: AS-3201

Indication

Disease Entry	ICD 11	Status	REF
Diabetic neuropathy	8C0Z	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 153948
  CAS Number: CAS 147254-64-6
  TTD Drug ID: DMD5QRS

Molecule-Related Drug Atlas

Drug(s) Targeting Aldose reductase (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[4]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[5]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[6]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[7]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[2]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[8]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[9]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[10]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[2]
M-16209	DMZ7YX3	Diabetic complication	5A2Y	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
UDP-glucuronosyltransferase 1A1	OTH1C8OJ	UD11_HUMAN	Biotransformations	[3]
UDP-glucuronosyltransferase 1A3	OTUEOER3	UD13_HUMAN	Biotransformations	[3]
UDP-glucuronosyltransferase 1A4	OT4PU620	UD14_HUMAN	Biotransformations	[3]
UDP-glucuronosyltransferase 1A9	OTPCHAFX	UD19_HUMAN	Biotransformations	[3]
UDP-glucuronosyltransferase 2B15	OTABTFU2	UDB15_HUMAN	Biotransformations	[3]
UDP-glucuronosyltransferase 2B4	OTSZZP0B	UD2B4_HUMAN	Biotransformations	[3]
UDP-glucuronosyltransferase 2B7	OT2Q71VQ	UD2B7_HUMAN	Biotransformations	[3]

References

• [1] ClinicalTrials.gov (NCT00101426) Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
• [3] Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochem Pharmacol. 2004 Apr 1;67(7):1269-78. doi: 10.1016/j.bcp.2003.11.010.
• [4] Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
• [5] Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
• [6] Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
• [7] Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
• [8] ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
• [9] Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
• [10] A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
• [11] Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.